<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10</volume><submitter>Nupur N</submitter><pubmed_abstract>Biopharmaceuticals are one of the fastest-growing sectors in the biotechnology industry. Within the umbrella of biopharmaceuticals, the biosimilar segment is expanding with currently over 200 approved biosimilars, globally. The key step towards achieving a successful biosimilar approval is to establish analytical and clinical biosimilarity with the innovator. The objective of an analytical biosimilarity study is to demonstrate a highly similar profile with respect to variations in critical quality attributes (CQAs) of the biosimilar product, and these variations must lie within the range set by the innovator. This comprises a detailed comparative structural and functional characterization using appropriate, validated analytical methods to fingerprint the molecule and helps reduce the econo</pubmed_abstract><journal>Frontiers in bioengineering and biotechnology</journal><pagination>832059</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8865741</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.</pubmed_title><pmcid>PMC8865741</pmcid><pubmed_authors>Rathore AS</pubmed_authors><pubmed_authors>Gulliarme D</pubmed_authors><pubmed_authors>Nupur N</pubmed_authors><pubmed_authors>Joshi S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.</name><description>Biopharmaceuticals are one of the fastest-growing sectors in the biotechnology industry. Within the umbrella of biopharmaceuticals, the biosimilar segment is expanding with currently over 200 approved biosimilars, globally. The key step towards achieving a successful biosimilar approval is to establish analytical and clinical biosimilarity with the innovator. The objective of an analytical biosimilarity study is to demonstrate a highly similar profile with respect to variations in critical quality attributes (CQAs) of the biosimilar product, and these variations must lie within the range set by the innovator. This comprises a detailed comparative structural and functional characterization using appropriate, validated analytical methods to fingerprint the molecule and helps reduce the econo</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-06-01T02:31:40.707Z</modification><creation>2024-10-16T14:54:24.49Z</creation></dates><accession>S-EPMC8865741</accession><cross_references><pubmed>35223794</pubmed><doi>10.3389/fbioe.2022.832059</doi></cross_references></HashMap>